Huntsman Carole
Chief Commercial Officer
Huntsman Carole has filed 3 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Mar 6, 2026.
On the most recent filing, Huntsman Carole is listed as Chief Commercial Officer at MADRIGAL PHARMACEUTICALS, INC. Inside the rolling window, Huntsman Carole reported no open-market purchases and 3 open-market sales totaling $1.7M in MDGL. The largest disclosed transaction in the window is a sale of 1,958 MDGL shares on Nov 21, 2025, worth $1.1M.
Companies traded
Other insiders at MDGL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Huntsman Carole made?
Huntsman Carole has filed 3 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.
Which companies does Huntsman Carole trade?
Huntsman Carole has filed SEC Form 4 disclosures for 1 company, including MDGL.
When was Huntsman Carole's most recent SEC Form 4 filing?
Huntsman Carole's most recent SEC Form 4 filing on Tracefour is dated Mar 6, 2026.
What is Huntsman Carole's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Huntsman Carole is listed as Chief Commercial Officer.
What is Huntsman Carole's total buy and sell value in the current window?
Inside the rolling retention window, Huntsman Carole bought $0 and sold $1.7M based on SEC Form 4 filings.
What was Huntsman Carole's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,958 MDGL shares on 2025-11-21, worth $1.1M, per SEC Form 4 filings.